1Q21 Investor Update
CREATING THE "MONSANTO OF CANNABIS"
Accelerated modification of cannabis plants to the highest levels of quality, stability and scale
DE
56
SOPH
Jan
■
Industry leadership will require specific genetic profiles
to produce desired taste, scent, and psychoactive
effects and ensure the product can be replicated
consistently at commercial scale
—
22nd Century Group, Inc.
Ability to control the expression of CBD, THC, CBG, CBN,
terpenes, and other cannabinoids is critical to financial
returns and quality metrics
Companies with deep IP and genetics capabilities will be
able to more easily move into new markets and
applications
Control of traits and consistency will command a
premium price and higher margin
22ND CENTURY HAS ESTABLISHED A LEADERSHIP POSITION IN GENETIC IP CRITICAL
TO HEMP/CANNABIS ACHIEVING ITS FULL COMMERCIAL POTENTIAL
11View entire presentation